Mutational profiles in HIV-1 protease correlated with...

Details Mutational profiles in HIV-1 protease correlated with... Mutational profiles in HIV-1 protease correlated with...

2008-10-30

2011-12-13

Parkin, Jeffrey S. (Department: 1648)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

C435S005000

Reexamination Certificate

active

08076062

ABSTRACT:
The present invention is directed to the field of nucleic acid diagnostics and the identification of base variation in target nucleic acid sequences. More particularly, the present invention relates to the use of such genotypic characterization of a target population of HIV and the subsequent association, i.e., correlation, of this information to phenotypic interpretation in order to correlate virus mutational profiles with drug resistance. The invention also relates to methods of utilizing the mutational profiles of the invention in drug development, i.e., drug discovery, drug design, drug modification, and therapy, treatment design, clinical management and diagnostic analysis.

REFERENCES:
patent: 327742 (1885-10-01), Uren
patent: 5631128 (1997-05-01), Kozal et al.
patent: 5650268 (1997-07-01), Kozal et al.
patent: 5856086 (1999-01-01), Kozal et al.
patent: 6221578 (2001-04-01), de Bethune et al.
patent: 6528251 (2003-03-01), de Bethune et al.
patent: 7058616 (2006-06-01), Larder et al.
patent: 7217506 (2007-05-01), De Meyer et al.
patent: 7292944 (2007-11-01), Larder et al.
patent: 7473524 (2009-01-01), Azijn et al.
patent: 7494768 (2009-02-01), Hertogs et al.
patent: 2003/0190603 (2003-10-01), Larder et al.
patent: 2004/0073378 (2004-04-01), Dehertogh et al.
patent: 2005/0124744 (2005-06-01), Demain
patent: 2005/0233312 (2005-10-01), De Meyer et al.
patent: 2008/0286754 (2008-11-01), Dehertogh et al.
patent: 2009/0352626 (2009-01-01), Hertogs et al.
patent: 2009/0162867 (2009-06-01), Hertogs et al.
patent: 2029123 (1991-05-01), None
patent: 406985 (1991-01-01), None
patent: 0 422 762 (1991-04-01), None
patent: 0 428 000 (1991-05-01), None
patent: 0 518 557 (1992-12-01), None
patent: 0 824 148 (1998-02-01), None
patent: 0 104 445 (2001-10-01), None
patent: 0 106 360 (2001-12-01), None
patent: 1605064 (2005-12-01), None
patent: 2002-199890 (2002-07-01), None
patent: WO 96/08580 (1996-03-01), None
patent: 97/27332 (1997-07-01), None
patent: 97/27480 (1997-07-01), None
patent: WO 97/27319 (1997-07-01), None
patent: 99/67428 (1999-12-01), None
patent: WO 99/67417 (1999-12-01), None
patent: WO-9961658 (1999-12-01), None
patent: WO-9961666 (1999-12-01), None
patent: WO-9967427 (1999-12-01), None
patent: 00/73511 (2000-12-01), None
patent: 00/78994 (2000-12-01), None
patent: 00/78996 (2000-12-01), None
patent: 01/79540 (2001-10-01), None
patent: 01/81624 (2001-11-01), None
patent: 01/95230 (2001-12-01), None
patent: 02/22076 (2002-03-01), None
patent: 02/33402 (2002-04-01), None
patent: 02/38792 (2002-05-01), None
patent: 02/083657 (2002-10-01), None
patent: 2004/022523 (2004-03-01), None
Yin et al. Overcoming HIV drug resistance through rational drug design based on molecular, biochemical, and structural profiles of HIV resistance. Cellular Molecular Life Sciences 2006, vol. 63, pp. 1706-1724.
Yee et al. Prospects for gene therapy using HIV-based vectors. Somatic Cell and Molecular Genetics, Nov. 2001, vol. 26, No. 1/6, pp. 159-174.
In the U.S. Patent and Trademark Office, Non-Final Office Action in re: U.S. Appl. No. 10/518,525, dated May 10, 2006, 9 pages.
In the U.S. Patent and Trademark Office, Final Office Action in re: U.S. Appl. No. 10/518,525, dated Feb. 7, 2007, 10 pages.
In the U.S. Patent and Trademark Office, Final Office Action in re: U.S. Appl. No. 10/518,525, dated Oct. 18, 2007, 6 pages.
In the U.S. Patent and Trademark Office, Non-Final Office Action in re: U.S. Appl. No. 10/519,436, dated Mar. 13, 2006, 11 pages.
In the U.S. Patent and Trademark Office, Non-Final Office Action in re: U.S. Appl. No. 10/519,436, dated Mar. 7, 2007, 14 pages.
In the U.S. Patent and Trademark Office, Non-Final Office Action in re: U.S. Appl. No. 10/519,436, dated Oct. 18, 2007, 8 pages.
In the U.S. Patent and Trademark Office, Non-Final Office Action in re: U.S. Appl. No. 10/519,436, dated Jun. 30, 2008, 10 pages.
In the U.S. Patent and Trademark Office, Non-Final Office Action in re: U.S. Appl. No. 10/519,436, dated Mar. 4, 2009, 10 pages.
In the U.S. Patent and Trademark Office, Non-Final Office Action in re: U.S. Appl. No. 10/519,436, dated Sep. 17, 2009, 13 pages.
In the U.S. Patent and Trademark Office, Non-Final Office Action in re: U.S. Appl. No. 10/519,035, dated Dec. 16, 2005, 6 pages.
In the U.S. Patent and Trademark Office, Non-Final Office Action in re: U.S. Appl. No. 10/399,920, dated Aug. 25, 2005, 14 pages.
In the U.S. Patent and Trademark Office, Final Office Action in re: U.S. Appl. No. 10/399,920, dated Aug. 4, 2006, 9 pages.
In the U.S. Patent and Trademark Office, Final Office Action in re: U.S. Appl. No. 10/399,920, dated May 2, 2007, 10 pages.
In the U.S. Patent and Trademark Office, Non-Final Office Action in re: U.S. Appl. No. 11/933,747, dated Aug. 7, 2009.
In the U.S. Patent and Trademark Office, Non-Final Office Action in re: U.S. Appl. No. 11/613,584, dated Mar. 12, 2009, 9 pages.
In the U.S. Patent and Trademark Office, Non-Final Office Action in re: U.S. Appl. No. 11/613,584, dated Apr. 15, 2010, 11 pages.
In the U.S. Patent and Trademark Office, Final Office Action in re: U.S. Appl. No. 10/519,436, dated May 11, 2010, 10 pages.
Bacheler et al., “Human Immunodeficiency Virus Type 1 Mutations Selected in Patients Failing Efavirenz Combination Therapy,”Antimicrobial Agents and Chemotherapy, 2000; 44(9):2475-2484.
Beerenwinkel et al., “Diversity and Complexity of HIV-1 Drug Resistance: A Bioinformatics Approach to Predicting Phenotype from Genotype,”PNAS, 2002; 99(2):8271-8276.
Clevenbergh et al., “Prevalence of Nonucleoside Reverse Transcriptase Inhibitor (NNRTI) Resistance-Associated Mutations and Polymorphisms in NNRTI-Naïve HIV-Infected Patients,”HIV Clin Trials, 2002; 3(1):36-44.
Craig et al., “HIV Protease Genotype and Viral Sensitivity to HIV Protease Inhibitors Following Saquinavir Therapy,”AIDS, 1998; 12:1611-1618.
DeScamps et al., “Line Probe Assay for Detection of Human Immunodeficiency Virus type 1 Mutations Conferring Resistance to Nucleoside Inhibitors of Reverse Transcriptase: Comparison with Sequence Analysis,”Journal of Clinical Microbiology, 1998:36(7):2143-2145.
Eshleman et al., Analysis of Human Immunodeficiency Virus Type 1 Drug Resistance in Children Receiving Nucleoside Analogue Reverse-Transcriptase Inhibitors plus Nevirapine, Nelfinavir, or Ritonavir (Pediatric AIDS Clinical Trials Group 377),Journal of Infectious Disease, 2001; 183:1732-1738.
Fodor, et al., “DNA Sequencing: Massively Parallel Genomics,”Science, 1997; 277:393-395.
Fukui, T., et al., “Cloning and Analysis of the Poly (3-Hydroxybutyrate-co-3-Hydroxyhexanoate) Biosynthesis Genes ofAeromonas caviae”, Journal Baceriology, 1997; 179(15):4821-4830.
Hertogs et al., “A Novel Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutational Pattern Confers Phenotypic Lamivudine Resistance in the Absence of Mutation 184V,”Antimicrobial Agents and Chemotherapy, 2000; 44(3):568-573.
Iversen et al., “Multidrug-Resistant Human Immunodeficiency Virus Type 1 Strains Resulting from Combination Antiretroviral Therapy”,Journal of Virology, 1996; 70(2):1086-1090.
Japour, et al., “Standardized Peripheral Blood Mononuclear Cell Culture Assay for Determination of Drug Susceptibilities of Clinical Human Immunodeficiency Virus Type 1 Isolates,”Antimicrobial Agents Chemotherapy, 1993; 37(5):1095-1101.
Kellam et al., “Recombinant Virus Assay: A Rapid, Phenotypic Assay for Assessment of Drug Susceptibility of Human Immunodeficiency Virus Type 1 Isolates,”Antimicrobial Agents and Chemotherapy, 1994; 38(1):23-30.
Kemp et al., “Analysis of 5000 HIV-1 Clinical Samples Reveals Complex Non-Nucleoside RT Inhibitor Resistance Patterns,”Antiviral Therapy, 1999; 4(Suppl 1):20.
Kichise et al., “Enhanced Accumulation and Changed Monomer Composition in Polyhydroxyalkanoate (PHA) Copolyester by in Vitro Evolution ofAeromonas caviaePHA Synthase,”Applied and Environmental Microbiology, 2002; 68(5):2411-2419.
Kim et al., &#

Affiliated with

Also associated with

Rating

Mutational profiles in HIV-1 protease correlated with... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Mutational profiles in HIV-1 protease correlated with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mutational profiles in HIV-1 protease correlated with... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4314283